Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy.

Moyle, G J; Buss, N E; Gazzard, B G

Moyle, G J; Buss, N E; Gazzard, B G.

J Acquir Immune Defic Syndr ; 30(4): 460-2, 2002 Aug 01.

Article in En | MEDLINE | ID: mdl-12138355

Subject(s)

Anticholesteremic Agents/administration & dosage; HIV Infections/complications; HIV Infections/drug therapy; HIV Protease Inhibitors/administration & dosage; Hypercholesterolemia/drug therapy; Hypercholesterolemia/etiology; Pravastatin/administration & dosage; Anticholesteremic Agents/adverse effects; Antiretroviral Therapy, Highly Active; HIV Protease Inhibitors/adverse effects; Humans; Male; Pravastatin/adverse effects; Viremia/drug therapy

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: HIV Infections / Pravastatin / HIV Protease Inhibitors / Hypercholesterolemia / Anticholesteremic Agents Type of study: Clinical_trials Limits: Humans / Male Language: En Journal: J Acquir Immune Defic Syndr Year: 2002 Document type: Article

Search on Google

XML

PubMed Links